Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

The Lancet Oncology
Lucio CrinòCaicun Zhou

Abstract

Results of two phase 3 trials have shown first-line bevacizumab in combination with chemotherapy improves clinical outcomes in patients with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC). The SAiL (MO19390) study was undertaken to assess the safety and efficacy of first-line bevacizumab combined with standard chemotherapy regimens in clinical practice. Between August, 2006, and June, 2008, patients with untreated locally advanced, metastatic, or recurrent non-squamous NSCLC were recruited to this open-label, single group, phase 4 study from centres in 40 countries. Eligible patients had histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent disease (stage IIIB-IV); an Eastern Cooperative Oncology Group performance status of 0-2; and adequate haematological, hepatic, and renal function. Patients received bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression. The primary endpoint was safety; analysis was by intention to treat (ITT). This study is registered with ClinicalTrials.gov, number NCT00451906. At the final data cutoff (July 24, 2009), an ITT population of ...Continue Reading

References

Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Aug 10, 2007·Journal of the National Cancer Institute·Frank A ScappaticciHerbert Hurwitz
May 1, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O MirF Goldwasser

❮ Previous
Next ❯

Citations

May 15, 2012·Cancer Immunology, Immunotherapy : CII·Runmei LiHui Li
Oct 12, 2011·Investigational New Drugs·George R Blumenschein
Aug 31, 2013·Current Treatment Options in Oncology·Ryan D GentzlerJyoti D Patel
Feb 18, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN SAVE-ONCO Investigators
Nov 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ReckD R Spigel
Nov 28, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-C SoriaUNKNOWN meta-analysis of bevacizumab in advanced NSCLC collaborative group
Jan 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Osamu TakahashiMichael S O'Reilly
Mar 30, 2012·Cancer Management and Research·Fernanda EstevinhoAntónio Araújo
Dec 7, 2013·Pathology Oncology Research : POR·Nora BittnerLajos Géczi
Sep 5, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C C ZhouY Z Zhu
Jun 20, 2014·Future Oncology·Enrica CapellettoGiorgio V Scagliotti
Jun 10, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·M Snee
Oct 16, 2014·Drugs·Gillian M Keating
Mar 29, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Filippo de MarinisUNKNOWN Italian Association of Thoracic Oncology
Aug 22, 2015·Expert Opinion on Drug Metabolism & Toxicology·Laure-Anne TeuwenLuc Dirix
Dec 31, 2015·Journal of Gastrointestinal Cancer·Fabian FinkelmeierJörg Trojan
Jul 23, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Madhusmita BeheraSuresh S Ramalingam
Aug 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Thomas J LynchUNKNOWN ARIES Study Investigators
Aug 19, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Daniel Morgensztern, Ramaswamy Govindan
Sep 28, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Wilfried Eberhardt
Feb 26, 2014·Seminars in Oncology·Simona CarnioGiorgio Vittorio Scagliotti
Feb 24, 2016·Future Oncology·Srinath SundararajanNicholas J Vogelzang
Mar 26, 2013·Human Pathology·Samaneh YazdaniHironobu Sasano
Dec 26, 2012·Critical Reviews in Oncology/hematology·Giuseppe AprileFabio Puglisi
Nov 20, 2012·Critical Reviews in Oncology/hematology·Athanasios G Pallis, Konstantinos N Syrigos
Jun 30, 2012·Pathologie-biologie·L StaudacherJ Trédaniel
Mar 1, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Olivier MirFrançois Goldwasser
Nov 10, 2011·Biochimica Et Biophysica Acta·Arman Jahangiri, Manish K Aghi
Apr 23, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chun-Ming TsaiYi-long Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Martin ReckChristian Manegold
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Eric DansinMartin Kohlhaeufl
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Natasha B LeighlChristian Manegold
© 2021 Meta ULC. All rights reserved